.Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BB02_RisedronicAcidAndCalcium.RisedronicAcidAndCalcium .Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BB02_RisedronicAcidAndCalcium.RisedronicAcidAndCalcium| name: | RisedronicAcidAndCalciumSequential | |
| ATC code: | M05BB02 | route: | oral |
| compartments: | 1 | |
| dosage: | 35 | mg |
| volume of distribution: | 14.5 | L |
| clearance: | 108 | ml/min |
| other parameters in model implementation | ||
Risedronic acid and calcium, sequential is a fixed-dose combination medication used to treat and prevent osteoporosis in postmenopausal women at risk for vitamin D and calcium deficiencies. Risedronic acid (risedronate) is a bisphosphonate that inhibits bone resorption, while calcium provides a supplement to maintain bone health. It is approved and in use today for osteoporosis management.
Pharmacokinetic parameters estimated for typical adult population as no direct sources found for the fixed-dose combination; values are primarily based on risedronic acid (risedronate) data for healthy adults administered orally. Calcium component does not impact risedronate PK if taken sequentially.